175 related articles for article (PubMed ID: 7851498)
21. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney.
Benigni A; Zola C; Corna D; Orisio S; Facchinetti D; Benati L; Remuzzi G
Am J Kidney Dis; 1996 Mar; 27(3):416-23. PubMed ID: 8604712
[TBL] [Abstract][Full Text] [Related]
22. Paracrine renal endothelin system in rats with liver cirrhosis.
Hocher B; Zart R; Diekmann F; Rohmeiss P; Distler A; Neumayer HH; Bauer C; Gross P
Br J Pharmacol; 1996 May; 118(2):220-7. PubMed ID: 8735618
[TBL] [Abstract][Full Text] [Related]
23. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
Holm P
Scand Cardiovasc J Suppl; 1997; 46():1-40. PubMed ID: 9265559
[TBL] [Abstract][Full Text] [Related]
24. Effects of Ro 47-0203 on endothelin-1 and sarafotoxin S6c-induced contractions of human bronchus and guinea-pig trachea.
Gater PR; Wasserman MA; Renzetti LM
Eur J Pharmacol; 1996 May; 304(1-3):123-8. PubMed ID: 8813593
[TBL] [Abstract][Full Text] [Related]
25. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats.
Schiffrin EL; Sventek P; Li JS; Turgeon A; Reudelhuber T
Br J Pharmacol; 1995 Aug; 115(8):1377-81. PubMed ID: 8564194
[TBL] [Abstract][Full Text] [Related]
26. Identification of specific intracellular domains of the human ETA receptor required for ligand binding and signal transduction.
Hashido K; Adachi M; Gamou T; Watanabe T; Furuichi Y; Miyamoto C
Cell Mol Biol Res; 1993; 39(1):3-12. PubMed ID: 8287069
[TBL] [Abstract][Full Text] [Related]
27. Nonpeptide endothelin receptor antagonists. I. Effects on binding and signal transduction on human endothelinA and endothelinB receptors.
Nambi P; Elshourbagy N; Wu HL; Pullen M; Ohlstein EH; Brooks DP; Lago MA; Elliott JD; Gleason JG; Ruffolo RR
J Pharmacol Exp Ther; 1994 Nov; 271(2):755-61. PubMed ID: 7965793
[TBL] [Abstract][Full Text] [Related]
28. Intrastriatal injection of endothelin evokes dopaminergic turning behaviour in rats through activation of the ETB receptor.
Webber KM; van den Buuse M
Brain Res; 1996 Jun; 724(2):180-5. PubMed ID: 8828566
[TBL] [Abstract][Full Text] [Related]
29. Endothelin ET
Vercauteren M; Trensz F; Pasquali A; Cattaneo C; Strasser DS; Hess P; Iglarz M; Clozel M
J Pharmacol Exp Ther; 2017 May; 361(2):322-333. PubMed ID: 28223322
[TBL] [Abstract][Full Text] [Related]
30. Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist.
Yuyama H; Noguchi Y; Fujimori A; Ukai M; Fujiyasu N; Ohtake A; Sato S; Sudoh K; Sasamata M; Miyata K
Eur J Pharmacol; 2004 Sep; 498(1-3):171-7. PubMed ID: 15363992
[TBL] [Abstract][Full Text] [Related]
31. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist.
Kaddoura S; Firth JD; Boheler KR; Sugden PH; Poole-Wilson PA
Circulation; 1996 Jun; 93(11):2068-79. PubMed ID: 8640984
[TBL] [Abstract][Full Text] [Related]
32. Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptors.
Nambi P; Pullen M; Wu HL; Lee D; Saunders D; Heys R; Aiyar N; Leber J; Elliott J; Brooks D; Ohlstein E; Ruffolo R
J Pharmacol Exp Ther; 1996 Jun; 277(3):1567-71. PubMed ID: 8667224
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart.
Peter MG; Davenport AP
Br J Pharmacol; 1996 Feb; 117(3):455-462. PubMed ID: 8821534
[TBL] [Abstract][Full Text] [Related]
34. Function and expression of endothelin receptor subtypes in the kidneys of spontaneously hypertensive rats.
Hocher B; Rohmeiss P; Zart R; Diekmann F; Vogt V; Metz D; Fakhury M; Gretz N; Bauer C; Koppenhagen K; Neumayer HH; Distler A
Cardiovasc Res; 1996 Apr; 31(4):499-510. PubMed ID: 8689641
[TBL] [Abstract][Full Text] [Related]
35. Identification and characterization of a novel endothelin receptor that binds both ETA- and ETB-selective ligands.
Nambi P; Pullen M; Kincaid J; Nuthulaganti P; Aiyar N; Brooks DP; Gellai M; Kumar C
Mol Pharmacol; 1997 Oct; 52(4):582-9. PubMed ID: 9380020
[TBL] [Abstract][Full Text] [Related]
36. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl) carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelinA and endothelinB receptors.
Masuda Y; Sugo T; Kikuchi T; Kawata A; Satoh M; Fujisawa Y; Itoh Y; Wakimasu M; Ohtaki T
J Pharmacol Exp Ther; 1996 Nov; 279(2):675-85. PubMed ID: 8930171
[TBL] [Abstract][Full Text] [Related]
37. Role and mechanism of endothelin-B receptors in mediating ET-1-induced vasoconstriction in pig skin.
Pang CY; Zhang J; Xu H; Lipa JE; Forrest CR; Neligan PC
Am J Physiol; 1998 Oct; 275(4):R1066-74. PubMed ID: 9756535
[TBL] [Abstract][Full Text] [Related]
38. X-ray structures of endothelin ET
Shihoya W; Nishizawa T; Yamashita K; Inoue A; Hirata K; Kadji FMN; Okuta A; Tani K; Aoki J; Fujiyoshi Y; Doi T; Nureki O
Nat Struct Mol Biol; 2017 Sep; 24(9):758-764. PubMed ID: 28805809
[TBL] [Abstract][Full Text] [Related]
39. Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats.
Gardiner SM; Kemp PA; March JE; Bennett T
Br J Pharmacol; 1994 Jul; 112(3):823-30. PubMed ID: 7921608
[TBL] [Abstract][Full Text] [Related]
40. Ca2+ signalling by endothelin receptors in rat and human cultured airway smooth muscle cells.
Maxwell MJ; Goldie RG; Henry PJ
Br J Pharmacol; 1998 Dec; 125(8):1768-78. PubMed ID: 9886769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
